TY - JOUR
T1 - Reduced baroreflex sensitivity and increased splenic activity in patients with severe obstructive sleep apnea
AU - Kaiser, Yannick
AU - Dzobo, Kim E.
AU - Ravesloot, Madeline J. L.
AU - Nurmohamed, Nick S.
AU - Collard, Didier
AU - Hoogeveen, Renate M.
AU - Verberne, Hein J.
AU - Dijkstra, Nynke
AU - de Vries, Nico
AU - Bresser, Paul
AU - Kroon, Jeffrey
AU - Stroes, Erik S. G.
AU - Reesink, Herre J.
N1 - Funding Information: YK and ESGS were supported by the Netherlands Heart Foundation CVON 2017–20 : generating the best evidence-based pharmaceutical targets for atherosclerosis [GENIUS II]). JK was supported by the Netherlands Organization for Scientific Research by a VENI Grant from ZonMW (Grant number 91619098 ) and by the Dutch Heart Foundation Senior Scientist Dekker Grant ( 2021T045 ). Funding Information: JK has received a research grant from Oxitope Pharma. NdV is a consultant for Philips and Olympus, member of the Medical Advisory Board of NightBalance, and researcher for Inspire, Nyxoah, and Jazz Pharmaceuticals. All other authors report no conflict of interest. ESGS has received research grants/support to his institution from Amgen, Sanofi and has served as a consultant for Amgen, Sanofi, Esperion, Novartis and Ionis Pharmaceuticals. Publisher Copyright: © 2022 Elsevier B.V.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - Background and aims: Severe obstructive sleep apnea (OSA) is associated with an increased risk of cardiovascular disease. Experimental evidence suggests that this risk may be mediated by chronic sympathetic hyperactivation and systemic inflammation, but the precise mechanisms remain to be unraveled. Our aim was to evaluate whether severe OSA patients are characterized by increased sympathetic and hematopoietic activity, potentially driving atherosclerosis. Methods: Untreated patients with severe OSA (apnea-hypopnea index (AHI) > 30 per hour) were matched with mild OSA patients (AHI<15 & >5 per hour) according to age, sex, and body mass index. Study objectives were to assess baroreflex sensitivity (BRS) and heart-rate variability (HRV) using continuous finger blood pressure measurements, hematopoietic activity in the bone marrow and spleen, and arterial inflammation with 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). Results: A total of 34 subjects, 17 per group, were included in the analysis. Mean age was 60.7 ± 6.2 years, 24 (70.6%) were male. Mean AHI was 40.5 ± 12.6 per hour in the severe OSA group, and 10.5 ± 3.4 per hour in the mild OSA group. Participants with severe OSA were characterized by reduced BRS (5.7 [4.6–7.8] ms/mmHg in severe vs 8.2 [6.9–11.8] ms/mmHg in mild OSA, p = 0.033) and increased splenic activity (severe OSA 18F-FDG uptake 3.56 ± 0.77 vs mild OSA 3.01 ± 0.68; p = 0.036). HRV, bone marrow activity and arterial inflammation were comparable between groups. Conclusions: Patients with severe OSA are characterized by decreased BRS and increased splenic activity. Randomized controlled trials are warranted to assess whether OSA treatment reduces sympathetic and splenic activity.
AB - Background and aims: Severe obstructive sleep apnea (OSA) is associated with an increased risk of cardiovascular disease. Experimental evidence suggests that this risk may be mediated by chronic sympathetic hyperactivation and systemic inflammation, but the precise mechanisms remain to be unraveled. Our aim was to evaluate whether severe OSA patients are characterized by increased sympathetic and hematopoietic activity, potentially driving atherosclerosis. Methods: Untreated patients with severe OSA (apnea-hypopnea index (AHI) > 30 per hour) were matched with mild OSA patients (AHI<15 & >5 per hour) according to age, sex, and body mass index. Study objectives were to assess baroreflex sensitivity (BRS) and heart-rate variability (HRV) using continuous finger blood pressure measurements, hematopoietic activity in the bone marrow and spleen, and arterial inflammation with 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). Results: A total of 34 subjects, 17 per group, were included in the analysis. Mean age was 60.7 ± 6.2 years, 24 (70.6%) were male. Mean AHI was 40.5 ± 12.6 per hour in the severe OSA group, and 10.5 ± 3.4 per hour in the mild OSA group. Participants with severe OSA were characterized by reduced BRS (5.7 [4.6–7.8] ms/mmHg in severe vs 8.2 [6.9–11.8] ms/mmHg in mild OSA, p = 0.033) and increased splenic activity (severe OSA 18F-FDG uptake 3.56 ± 0.77 vs mild OSA 3.01 ± 0.68; p = 0.036). HRV, bone marrow activity and arterial inflammation were comparable between groups. Conclusions: Patients with severe OSA are characterized by decreased BRS and increased splenic activity. Randomized controlled trials are warranted to assess whether OSA treatment reduces sympathetic and splenic activity.
KW - Arterial inflammation
KW - F-FDG PET/CT
KW - Hematopoietic activity
KW - Obstructive sleep apnea syndrome
KW - Sympathetic activity
UR - http://www.scopus.com/inward/record.url?scp=85123778186&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123778186&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.atherosclerosis.2022.01.004
DO - https://doi.org/10.1016/j.atherosclerosis.2022.01.004
M3 - Article
C2 - 35114557
SN - 0021-9150
VL - 344
SP - 7
EP - 12
JO - Atherosclerosis
JF - Atherosclerosis
ER -